Eli Lilly and Company

Joslin Diabetes Center, Inc.

Marcadia Biotech, Inc.

Louis Vignati

Michael R Jirousek

Lawrence E Stramm

Douglas Kirk Ways

George Liang King

William Terry Johnson

Lloyd Paul Aiello

Fatima Emitsel Yakubu-Madus

Richard Dennis DiMarchi

Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.

Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146

Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.

Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof

Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.

Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-&lsqb;N,N&prime;-1,1&prime;-((2&Prime;-ethoxy)-3&prime;&Prime;(O)-4&prime;&Prime;-(N,N-dimethylamino)-butane)-bis-(3,3&prime;-indolyl)&rsqb;-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for VEGF related diseases

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.

Therapeutic treatment for VEGF related ocular diseases

A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2'-ethoxy)-3''(O)-4''-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.

Growing community of inventors

Indianapolis, IN, United States of America

Louis Vignati